ArticleClinical transplantation2026
Hypothermic Machine Perfusion in Deceased Donor Kidney Transplantation: Provider and Transplant Center Practices and Perspectives.
Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypothermic machine perfusion (HMP), an organ preservation technique used in deceased donor kidney transplantation, improves early outcomes compared to traditional static cold storage while also providing a loosely validated organ viability assessment.
methodsWe designed a survey to better understand the practices, perceptions, and barriers to utilization of HMP. Surgeons, nephrologists, and coordinators were invited to participate in the survey via email.
resultsRespondents (90% transplant surgeons) from 88 transplant centers which utilize HMP (35% of active kidney transplant centers) participated, representing 63% of total transplant volume in 2024. Respondents strongly agreed that HMP is helpful in kidney selection (92%), reduces delayed graft function (90%), and allows for scheduling flexibility (91%). A majority (74%) answered that the Organ Procurement Organization (OPO exclusively pumps kidneys. The most cited barrier to HMP use was OPO refusal (58%). Thresholds for resistance and flow varied widely with over 2/3 of respondents citing a specified acceptable cut-off. Most respondents answered "sometimes" (60%) or "yes" (20%) that they would decline a kidney if HMP could not be accomplished for a kidney they wished to be pumped. Perceived pitfalls were underutilization of kidneys due to incorrect or inaccurate perfusion parameters, logistical challenges and costs of pumping, inexperience and technical difficulties leading to organ or vasculature injury, and lack of standardization in practice.
conclusionsHMP is used as a tool to assess organ viability and to overcome logistical hurdles by improving flexibility in operative timing. OPOs play a critical role in the ability to perform HMP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.